Sevinç Jakab

Sevinç Jakab

Auto-generated profile, based on publicly available information

Sevinç Jakab

COS, Centre for Organismal Studies Heidelberg, Department of Developmental Biology/Physiology, Heidelberg University 1 , 69120 Heidelberg

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
MJMoritz Jakab
Moritz Jakab
KLKi Hong Lee
Ki Hong Lee
AUAlexey Uvarovskii
Alexey Uvarovskii
SOSvetlana Ovchinnikova
Svetlana Ovchinnikova
SKShubhada R. Kulkarni
Shubhada R. Kulkarni
HAHellmut Augustin
Hellmut Augustin
In metastasis, cancer cells travel around the circulation to colonize distant sites. Due to the rarity of these events, the immediate fates of metastasizing tumor cells (mTCs) are poorly understood while the role of the endothelium as a dissemination interface remains elusive. Using a newly developed combinatorial mTC enrichment approach, we provide a transcriptional blueprint of the early colonization process. Following their arrest at the metastatic site, mTCs were found to either proliferate intravascularly or extravasate, thereby establishing metastatic latency. Endothelial-derived angiocrine Wnt factors drive this bifurcation, instructing mTCs to follow the extravasation–latency route. Surprisingly, mTC responsiveness towards niche-derived Wnt was established at the epigenetic level, which predetermined tumor cell behavior. Whereas hypomethylation enabled high Wnt activity leading to metastatic latency, methylated mTCs exhibited low activity and proliferated intravascularly. Collectively the data identify the predetermined methylation status of disseminated tumor cells as a key regulator of mTC behavior in the metastatic niche.

3 January 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
RWRoberto Würth
Roberto Würth
EDElisa Donato
Elisa Donato
LMLaura L. Michel
Laura L. Michel
MSMassimo Saini
Massimo Saini
LBLisa Becker
Lisa Becker
ATAndreas Trumpp
Andreas Trumpp
Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively study disease progression and therapy responses. Here we present the establishment of long-term CTC-derived organoids from female individuals with metastatic breast cancer. Multiomics analysis of CTC-derived organoids along with preclinical modeling with xenografts identified neuregulin 1 (NRG1)–ERBB2 receptor tyrosine kinase 3 (ERBB3/HER3) signaling as a key pathway required for CTC survival, growth and dissemination. Genome-wide CRISPR activation screens revealed that fibroblast growth factor receptor 1 (FGFR1) signaling serves a compensatory function to the NRG1–HER3 axis and rescues NRG1 deficiency in CTCs. Conversely, NRG1–HER3 activation induced resistance to FGFR1 inhibition, whereas combinatorial blockade impaired CTC growth. The dynamic interplay between NRG1–HER3 and FGFR1 signaling reveals the molecular basis of cancer cell plasticity and clinically relevant strategies to target it. Our CTC organoid platform enables the identification and validation of patient-specific vulnerabilities and represents an innovative tool for precision medicine.

1 June 2021 in Development
Verified
Journal Article
Open access
PDF file
SGSevinç Gücüm
Sevinç Gücüm
RSRoman Sakson
Roman Sakson
MHMarcus Hoffmann
Marcus Hoffmann
VGValerian Grote
Valerian Grote
CBClara Becker
Clara Becker
JWJoachim Wittbrodt
Joachim Wittbrodt
Defects in the evolutionarily conserved protein-glycosylation machinery during embryonic development are often fatal. Consequently, congenital disorders of glycosylation (CDG) in human are rare. We modelled a putative hypomorphic mutation described in an alpha-1,3/1,6-mannosyltransferase (ALG2) index patient (ALG2-CDG) to address the developmental consequences in the teleost medaka (Oryzias latipes). We observed specific, multisystemic, late-onset phenotypes, closely resembling the patient's syndrome, prominently in the facial skeleton and in neuronal tissue. Molecularly, we detected reduced levels of N-glycans in medaka and in the patient's fibroblasts. This hypo-N-glycosylation prominently affected protein abundance. Proteins of the basic glycosylation and glycoprotein-processing machinery were over-represented in a compensatory response, highlighting the regulatory topology of the network. Proteins of the retinal phototransduction machinery, conversely, were massively under-represented in the alg2 model. These deficiencies relate to a specific failure to maintain rod photoreceptors, resulting in retinitis pigmentosa characterized by the progressive loss of these photoreceptors. Our work has explored only the tip of the iceberg of N-glycosylation-sensitive proteins, the function of which specifically impacts on cells, tissues and organs. Taking advantage of the well-described human mutation has allowed the complex interplay of N-glycosylated proteins and their contribution to development and disease to be addressed.

7 November 2025 in Biology Open
Verified
Journal Article
Open access
KPKaisa Pakari
Kaisa Pakari
SJSevinç Jakab
Sevinç Jakab
JRJohanna Rasch
Johanna Rasch
ESEncarnación Sánchez Salvador
Encarnación Sánchez Salvador
BWBeate Wittbrodt
Beate Wittbrodt
TTThomas Thumberger
Thomas Thumberger
Creating hypomorphic mutations is crucial to study gene function in vivo, especially when null mutations result in (embryonic) lethality. This applies to enzymes involved in glycosylation that, when mutated in human patients, cause the disease congenital disorders of glycosylation (CDG). In order to resemble patient condition, it would be ideal to acutely modulate the proteins in question to directly interfere with protein levels of such essential enzymes. These methods offer to establish pathogenic enzyme levels resembling net enzyme activity reported in patients suffering from CDG, with phosphomannomutase 2-CDG (PMM2-CDG) as the most common form. We established an auxin-inducible acute protein knockdown system for the use in the teleost fish medaka (Oryzias latipes) by combining an improved degron (AID2) technology with an mAID-nanobody targeting endogenously GFP-tagged Pmm2 protein. We generated a fishline expressing a functional Pmm2-GFP fusion protein, by single copy integration of GFP into the pmm2 locus. Upon induction, the degron system efficiently reduced Pmm2-GFP levels and enzyme activity, recapitulating the activity level of the hypomorphic mutations associated with PMM2-CDG in patients. This broadly applicable approach enables the investigation of CDG disease mechanisms during early embryonic development through reduction of protein abundance, mimicking hypomorphic mutations and thus substantially expanding the range of the genetic toolbox.

23 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KPKaisa Pakari
Kaisa Pakari
SJSevinç Jakab
Sevinç Jakab
ESEncarnación Sánchez Salvador
Encarnación Sánchez Salvador
CTChristian Thiel
Christian Thiel
JWJoachim Wittbrodt
Joachim Wittbrodt
TTThomas Thumberger
Thomas Thumberger
Creating hypomorphic mutations are crucial to study gene function in vivo , especially when null mutations result in (embryonic) lethality. This is especially the case for enzymes involved in glycosylation that, when mutated in human patients, are causing the disease congenital disorders of glycosylation (CDG). To resemble the patient conditions, it would be ideal to acutely modulate the proteins in question to directly interfere with protein levels of such essential enzymes. These methods offer to establish pathogenic enzyme levels resembling net enzyme activity reported from patients suffering from CDG, with Phosphomannomutase 2 - CDG (PMM2-CDG) as the most common form. We established an auxin-inducible acute protein knockdown system for the use in the teleost fish medaka ( Oryzias latipes ) by combining an improved degron (AID2) technology with a mAID-nanobody targeting endogenously GFP-tagged Pmm2 protein. We generated a fishline expressing a functional Pmm2-GFP fusion protein, by single copy integration of GFP into the pmm2 locus. Upon induction, the degron system efficiently reduced Pmm2-GFP levels and enzyme activity, recapitulating the activity level of the hypomorphic mutations associated with PMM2-CDG in patients. This broadly applicable approach enables the investigation of CDG disease mechanisms during early embryonic development through reduction of protein abundance mimicking hypomorphic mutations and thus substantially expands the range of the genetic toolbox. Summary Statement: The combination of TIR1F74G and mAID-GFP-nanobody enables efficient acute knockdown of endogenously GFP-tagged proteins in medaka. This approach successfully reduced Pmm2 enzyme activity to pathological levels as seen in PMM2-CDG patients.